185750 — Chong Kun Dang Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00
- KR₩1tn
- KR₩1tn
- KR₩2tn
- 94
- 76
- 97
- 100
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,079,338 | 1,303,006 | 1,343,559 | 1,488,345 | 1,669,404 |
Cost of Revenue | |||||
Gross Profit | 404,279 | 489,140 | 495,818 | 542,639 | 662,202 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,005,684 | 1,179,070 | 1,248,801 | 1,382,351 | 1,422,202 |
Operating Profit | 73,654 | 123,936 | 94,759 | 105,994 | 247,203 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 71,821 | 121,839 | 80,594 | 97,165 | 241,598 |
Provision for Income Taxes | |||||
Net Income After Taxes | 52,975 | 90,405 | 42,356 | 79,978 | 213,602 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 53,882 | 91,633 | 42,720 | 80,953 | 212,521 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 53,882 | 91,633 | 42,720 | 80,953 | 212,521 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4,142 | 6,965 | 3,266 | 6,541 | 16,654 |
Dividends per Share |